SciSparc’s subsidiary NeuroThera Labs Initiates Phase IIb Clinical Trial Site At Hannover Medical School In Germany For SCI-110, Proprietary Cannabinoid-Based Treatment Candidate For Tourette Syndrome In Adults

뉴스 본문을 불러오고 있어요.

SciSparc’s subsidiary NeuroThera Labs Initiates Phase IIb Clinical Trial Site At Hannover Medical School In Germany For SCI-110, Proprietary Cannabinoid-Based Treatment Candidate For Tourette Syndrome In Adults | 웨이프 WAPE

SciSparc’s subsidiary NeuroThera Labs Initiates Phase IIb Clinical Trial Site At Hannover Medical School In Germany For SCI-110, Proprietary Cannabinoid-Based Treatment Candidate For Tourette Syndrome In Adults

기사 요약

관련 종목

댓글 —